Vidcast:  https://youtu.be/RMPpAQAprE4   Reports on the two mRNA vaccines Americans are receiving were published just days ago in the New England Journal of Medicine by Moderna and Pfizer with their academic collaborators.  Both vaccines trigger antibodies that neutralize the original predominant Wuhan strain and the British B.1.117 variants but have reduced though still lethal activity against the South African B.1.351 variant.   Using sera from vaccinated Americans, the Moderna-NIH team demonstrate equally effective neutralizing antibody levels for the prevalent original strain and the British B.1.1.7 variant.  Moderna-induced antibody is nearly 10-fold less effective against the South African B.1.351 variant, but it does neutralize.   The Pfizer-BioNTech-University of Texas team report the effectiveness of their vaccine-induced antibodies against the prevalent CoVid strain as well as against the South African strain.  The antibody strength against the latter was reduced by two-thirds but still effective.     As yet, there is no compelling study data on either vaccine for the Brazilian P1 variant.   https://www.nejm.org/doi/pdf/10.1056/NEJMc2102179?query=pfw&jwd=000013110419&jspc=MPD https://www.nejm.org/doi/pdf/10.1056/NEJMc2102017?query=pfw&jwd=000013110419&jspc=MPD   #CoVid #moderna #pfizer #vaccine #wuhan #b117 #b1351